Pharmafile Logo

Abstract Highlights from EHA 2022 : A Spotlight on CLL

- PMLiVE

Spotlight on CLL

Ahead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Prof John Gribben, UK, on the most important abstracts to look out for in CLL. Here are some of the highlights:

  1. Big interest in combining ibrutinib and venetoclax with two studies reported, both considering eradicating minimal residual disease (MRD) and how important that is:
    • Ph 3 FLAIR – interim data – at the 2-year mark when patients are discontinuing treatment, 89% of those patient’s bone marrow was MRD negative and 97% of patient’s blood was negative. This wasn’t seen with ibrutinib monotherapy, showing the strength of adding venetoclax to the combination.
    • Ph 2 CAPTIVATE with different treatment arms; some fixed duration and some driven by the endpoint. Translational data reported on the dynamics of looking at MRD, what cells are left, and do they differ – are we selecting out resistant variants? All important questions being addressed.
    • Combinations are being submitted for approval with it now being important to understand who the suitable patient is compared to the other available choices.
  2. Six-year follow-up data with venetoclax monotherapy in patients with 17p deletion – ORR approx. 77%, median OS >5yrs which is a great advantage for this patient population compared to the past, and median PFS of 28 months. Although we are moving beyond venetoclax monotherapy, this shows the level of efficacy that is being achieved.
  3. Update on the Ph 2 BRUIN study with pirtobrutinib and the patients with CLL who have had a median of 3 prior lines of therapy, meaning they are already heavily pre-treated with 86% having received a prior BTK inhibitor. Good responses are seen and now waiting to see how durable these responses are in terms of longer follow-up to see the long-term benefit.

You can also watch the full video here

About Medscape:
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. Medscape is the leading online global destination for physicians and healthcare professionals, providing over 5 million members with the latest medical news, expert opinion, and precision education (CME and CPD) to improve clinical practice and advance health outcomes. Medscape’s unrivalled membership reach and therapeutic expertise deliver education across 30+ specialties in 40+ learning formats, using the latest digital and live technology.

This content was provided by Medscape Education Global

Company Details

 Latest Content from  Medscape Education Global 

Part 3 of the Medscape video series #EHA

Ahead of  Europe’s largest hematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer, interviews Dr. Naval Daver on the most important abstracts to look out for in Myeloid and...

Part 2 of the Medscape video interview series

Ahead of Europe’s largest haematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer interviews Dr. John Gribben on the most important abstracts to look out for in CLL and the...

A Medscape Oncology exclusive preview

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. We are the largest medical education provider, delivering precision education for actionable outcomes across 30+ specialties in...

Part 1 of the Medscape video interview series

Ahead of  Europe’s largest hematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer, interviews Dr Loretta Nastoupil on the most important abstracts to look out for at EHA in lymphoma...

Medscape: Connect to the conversation

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. We are the largest medical education provider, delivering precision education for actionable outcomes across 30+ specialties in...

A Medscape 4-part video interview series

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. We are the largest medical education provider, delivering precision education for actionable outcomes across 30+ specialties in...